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four weeks of treatment. Thus, TCP once daily is the most
cost-effective treatment regime. In addition, when com-
paring current treatment practice (twice daily calcipotriol
applied for 8 weeks) to the once daily application of the
TCP for 4 weeks, it will reduce the treatment cost for pso-
riasis in Sweden by 46.2%. CONCLUSION: This study
demonstrates that TCP applied once daily is both cost-
effective and a cost-minimising treatment strategy, which
offers psoriasis patients a convenient and highly effective
treatment regime with a rapid onset of action.
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Despite longstanding use of Methotrexate (MTX) and
Cyclosporin A (CsA) in patients with severe psoriasis,
true comparative evidence derived from a RCT evaluat-
ing these systemic therapies was still lacking. Our
prospective, double blinded randomised comparison of
16 weeks treatment with MTX or CsA in 85 patients
showed comparable effectiveness and quality of life 
(Heydendael, submitted). The question arises, whether
other aspects, including costs of treatment of psoriasis,
side effects of subjective perspectives could be deciding
factors in treatment decision making; especially consider-
ing the different retail prices for MTX and CsA. OBJEC-
TIVES: To document the process of treatment of psoriasis
with MTX or CsA and follow-up in terms of resource
utilisation and associated costs. METHODS: Additional
data on direct medical and nonmedical costs and indirect
costs were collected for all 85 randomised patients up 
to 1 year after randomisation, and a cost minimisation
analysis was set up according to a societal perspective.
RESULTS: The average cumulative costs associated with
16 weeks treatment was €1,593 in MTX and €2,113 in
CsA (€520 difference favouring MTX), whereas 36 weeks
of follow up generated €2,417 (MTX) and €2,306 (CsA)
(difference: €111 in favour of CsA). Overall costs after
one year lead to an overall difference of €409 in favour
of MTX on a total cost of €4010 (10%). CONCLU-
SIONS: Economic arguments are not a deciding factor in
decision making between MTX or CsA for treatment of
severe psoriasis, as differences are small and costs associ-
ated with treatment and follow up management are gen-
erated by a variety of resources utilised, than costs of
systemic therapy alone.
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OBJECTIVES: The purpose of the evaluation is to show
the resource utilization and related costs per year as well
as per ﬂare for patients suffering from atopic dermatitis
in Switzerland from patients’ and third-party payers’ per-
spective. METHODS: Multi-center, retrospective cost-of-
illness study. Information as demographic characteristics,
number of ﬂares per year, consultations, hospitalizations,
cures and out-of-pocket expenditures as for e.g. OTC-
medication was collected with a patient-questionnaire.
Resource utilization of outpatient care was gained from
patient’s records. Direct and indirect costs were consid-
ered. RESULTS: Three ofﬁce-based pediatricians, two
ofﬁce-based dermatologists and two dermatology hospi-
tals participated. Sixty-ﬁve patients are included in this
study until now. Thirty-four patients sent back the ques-
tionnaire (52%). Mean age of patients is 17 years (1–70
years); about 42% are female. About 34% of the patients
have a mild course of disease; about 36% suffer from 
a moderate and 30% from a severe or extreme severe
course of disease. On average, 4.0 (SD 3.7) ﬂares per year
were reported by the patients. Two out of 31 patients
(6.5%) require hospitalization due atopic dermatitis per
year. From the patients’ perspective the main cost drivers
are OTC-medication and skin care products with annual
costs of CHF 360 per patient. Patients’ expenses for
special investigations and other devices for e.g. special
clothes and nutrition are about CHF 355 per patient. 
For additional treatment (e.g. psychotherapeutics and/or
naturopathy) patients spent about CHF 85 per year.
CONCLUSION: These preliminary results show that out-
of-pocket expenses per patient and year amount about
CHF 800. The study is still ongoing and ﬁnal cost data
from the third party payers’ perspective are under evalu-
ation until August 2002.
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OBJECTIVES: To estimate the resource utilization and
related costs per ﬂare and per year for patients suffering
from atopic dermatitis in Germany from patients’ and 
the third-party payers’ perspective. METHODS: Multi-
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center, cross-sectional cost-of-illness study. Information
as demographic characteristics, consultations, hospital-
izations, rehabilitations, out-of-pocket-expenditures as
for OTC-medication, copayment, skin care products 
and absence from work was collected with a semi-
standardized patient-questionnaire. Resource utilization
of outpatient care was gained from patients’ records.
Direct and indirect costs were considered. RESULTS: 16
centers—10 ofﬁce-based dermatologists, 4 ofﬁce-based
pediatricians, 1 outpatient unit of a dermatology hospi-
tal and 1 patient organization participated. Until now,
189 patients were enrolled at the medical centers. 153
patient questionnaires were sent back (including 53 from
patients of the patient organisation). Mean age of patients
is 24 years (1–71 years) and about 46% are male. About
27% of the patients have a mild course of disease, about
36% a moderate and about 37% a severe or very severe
course of disease. Six out of 153 patients were hospital-
ized due to the current ﬂare (4%). On average, patients’
expenses for OTC-medication and skin care products are
€164 per year, for additional treatment e.g. psycho-
therapy or naturopathy €62 per year and for e.g. special
clothes or nutrition €349 per year. CONCLUSIONS:
Because the study is still ongoing, annual cost data from
the third party payers’ perspective is under evaluation,
and will be ﬁnalized not later than August 2002. But these
preliminary results show that patients and their families
bear are remarkable amount of the annual costs (about
€575) by themselves.
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OBJECTIVE: To compare the cost-effectiveness of an
Elidel (pimecrolimus cream 1%) in the long-term man-
agement of children with atopic dermatitis. METHODS:
Data were taken from a double-blind, multicenter, ran-
domized, parallel-group study. Patients were randomised
(2 :1) to receive pimecrolimus treatment paradigm 
(i.e. emollients, pimecrolimus, medium potency topical
corticosteroids) or standard of care (emollients, vehicle,
medium potency topical corticosteroids). The study was
conducted in children and adolescents (2 to 18 years of
age, 474 patients on pimecrolimus and 237 patients on
standard of care). Costs were estimated by linking sever-
ity of disease as deﬁned by Investigator’s Global Assess-
ment (IGA) to average treatment costs. Drug costs were
estimated from the clinical trial data. Efﬁcacy was mea-
sured in number of patients with 0 ﬂares over 12 months
(“successfully treated patient”, STP) and average number
of ﬂares as reported in the clinical trial. RESULTS: In 
the children and adolescent study, 68.4% of patients on
pimecrolimus and 43.5% of patients on standard of care
had no ﬂare over the total study period of 12 months, a
difference of 24.9%. The average number of ﬂares in 
the pimecrolimus treatment group was 0.48, compared to
3.36 in the standard of care group, a reduction of 2.88
ﬂares. Patients on pimecrolimus cost GBP 1009, patients
on standard of care GBP 448, an incremental cost of GBP
561 over 12 months. 4.0 patients needed to be treated to
achieve one STP, the cost per STP was GBP 2255 and the
cost per ﬂare avoided was GBP 195. The results were sen-
sitive to the assumption of drug substance used, which is
closely linked to the cost of treatment. CONCLUSIONS:
Pimecrolimus has a very reasonable cost-effectiveness as
measured by the incremental cost per additional success-
fully treated patient and the incremental cost per ﬂare
avoided.
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OBJECTIVE: To estimate and compare the long-term
consequences of IOP control of travoprost, latanoprost
and timolol. METHOD: Daily IOP average, variance,
minimum, and maximum were derived from a 12-month
randomised, double-masked double-dummy, phase III
multi-centre clinical trial comparing travoprost 0.004%
od, latanoprost 0.005% od and timolol 0.5% bid.
Patients had POAG or OH, and IOP was measured at
weeks 2, 12, 24 and 48 at 8:00 am, 10:00 am and 4:00
pm. The Stewart discriminant functions were applied fol-
lowed by a step-by-step threshold responder analysis. The
statistical unit was eye and a second interaction order
analysis of variance was performed including eye, 
time, treatment, and investigator as variables. Sensitivity
analysis was performed on the 5th to 95th-percentile 
range of the discriminant empirical distribution function.
RESULTS: Five hundred and ninety-six patients were ran-
domly assigned to travoprost, timolol, or latanoprost.
Travoprost patients’ daily IOP average was signiﬁcantly
lower than timolol (-1.3mmHg, P < 0.0001) and
latanoprost (-0.3mmHg, P < 0.001). Similar results were
found on daily IOP minimal value (respectively -1.3mm
Hg, P < 0.0001; -0.3mmHg, P < 0.004) and daily IOP
maximal value (respectively -1.5mmHg, P < 0.0001; 
-0.3mmHg, P < 0.02). No difference was found on IOP
variance between the prostaglandins (P < 0.25) while
timolol patients had a higher estimate (-0.60; P < 0.004).
If eight timolol patients were treated instead with
latanoprost, one new VFD would be avoided over ﬁve
